切换至 "中华医学电子期刊资源库"

中华胃肠内镜电子杂志 ›› 2018, Vol. 05 ›› Issue (01) : 38 -40. doi: 10.3877/cma.j.issn.2095-7157.2018.05.005

所属专题: 文献

论著

埃索美拉唑预防氯吡格雷相关性胃黏膜损伤的研究
张姝翌1, 王树森1, 董默1, 石磊1, 李彦如1, 李文1,()   
  1. 1. 300100 天津,天津人民医院内镜中心
  • 收稿日期:2018-02-01 出版日期:2018-02-15
  • 通信作者: 李文
  • 基金资助:
    天津市卫计委科技基金重点项目(2015KR09); 天津市科技计划项目(14RCGFSY00151)

The study of prevention effect of esomeprazole on clopidogrel-induced gastric mucosal injury

Shuyi Zhang1, Shusen Wang1, Mo Dong1, Lei Shi1, Yanru Li1, Wen Li1,()   

  1. 1. Digestive Endoscopy Center, Tianjin Union Medical Center, Tianjin 300100, China
  • Received:2018-02-01 Published:2018-02-15
  • Corresponding author: Wen Li
  • About author:
    Corresponding author: Li Wen, Email:
引用本文:

张姝翌, 王树森, 董默, 石磊, 李彦如, 李文. 埃索美拉唑预防氯吡格雷相关性胃黏膜损伤的研究[J]. 中华胃肠内镜电子杂志, 2018, 05(01): 38-40.

Shuyi Zhang, Shusen Wang, Mo Dong, Lei Shi, Yanru Li, Wen Li. The study of prevention effect of esomeprazole on clopidogrel-induced gastric mucosal injury[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2018, 05(01): 38-40.

目的

探讨埃索美拉唑是否可以预防氯吡格雷导致的胃黏膜损伤。

方法

120只SD大鼠随机分为3组,每组40只,分别给予生理盐水、氯吡格雷、埃索美拉唑联合氯吡格雷灌胃。分别于给药后7 d、14 d、21 d和28 d处死大鼠,使用HE染色对胃黏膜进行组织病理学观察,使用Guth法对胃黏膜损伤进行评分。

结果

埃索美拉唑可显著降低胃黏膜损伤的发生率(65.0% vs 42.5%,P=0.044)。用药后7 d开始,单用氯吡格雷组小鼠胃黏膜出现明显损伤,损伤评分在14 d达到高峰(6.85±0.99),而联合用药组在各时间点胃黏膜损伤的程度均较单用氯吡格雷组更轻微(P<0.01),且损伤程度随用药时间延长无显著变化。

结论

氯吡格雷可导致胃黏膜损伤,且损伤程度在14 d达到高峰,而埃索美拉唑可有效预防氯吡格雷相关性胃黏膜损伤。

Objective

To evaluate the prevention effect of esomeprazole on clopidogrel-induced gastric mucosal lesions.

Methods

One hundred and twenty SD rats were divided into three groups randomly, which were intragastric administrated with normal saline, clopidogrel and esomeprazole combined with clopidogrel, respectively.The rats were executed after 7 days, 14 days, 21 days and 28 days, 10 rats for each group each time, then the stomach mucosas were observed and the scores of gastric mucosal injury were evaluated by using Guth system.

Results

Esomeprazole could significantly reduce the incidence of mucosal injury (65.0% vs 42.5%, P=0.044). The scores of ulcer index of combined group were lower than that of clopidogrel group.The degree of injury of combined group did not change significantly over time.

Conclusions

Clopidogrel could induce gastric mucosal injury. Esomeprazole could effectively prevent clopidogrel-induced gastric mucosal injury.

表1 各组大鼠胃黏膜损伤评分比较(分)
[1]
Tran H, Anand SS.Oral antiplatelet therapy in cerebrovascular disease,coronary artery disease,and peripheral arterial disease[J].JAMA,2004, 92(15):1867-1874.
[2]
Chan FK, Ching JY, Hung LC,et al.Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding[J].N Engl J Med,2005,352(3):238-244.
[3]
陈伟伟,高润霖,刘力生,等.《中国心血管病报告2016》概要[J].中国循环杂志,2017,(6):521-530.
[4]
Ho PM, Maddox TM, Wang L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome[J].JAMA,2009,301(9):937-944.
[5]
Gilard M, Arnaud B, Cornily JC,et al.Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized,double-blind OCLA (Omeprazole CLopidogrel Aspirin) study[J].J Am Coll Cardiol,2008,51(3):256-260.
[6]
Angiolillo DJ, Badimon JJ, Saucedo JF,et al.A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial[J].Eur Heart J,2011,32(7):838-846.
[7]
潘国忠,王海滨,邹阳春,等.质子泵抑制剂埃索美拉唑对氯吡格雷抗血小板作用的影响[J].中华老年心脑血管病杂志,2011,13(1):42-44.
[8]
张秋瓒,王邦茂,杨倩,等.氯吡格雷联合阿司匹林对大鼠胃黏膜的影响及TNF-α、VEGF表达研究[J].中国现代医学杂志,2014,24(5):45-50.
[9]
Vernaz N, Rollason V, Adlere L,et al.Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines[J].Pharmacol Res Perspect,2016,4(3):e00234.
[10]
姜宗丹,张振玉,汪志兵,等.氯吡格雷对人胃黏膜上皮细胞损伤机制的研究[J]. 中华消化杂志,2011,31(11):724-728.
[11]
田珺琪,张志广,李熳,等.双联抗血小板药物对大鼠小肠的损伤及其机制[J].天津医科大学学报,2014,(5):350-353.
[1] 郭宝磊, 符伟国, 郭大乔, 史振宇, 王利新, 唐骁, 李炜淼. CYP2C19基因多态性与下肢动脉硬化闭塞症腔内治疗术后再缺血的相关性研究[J]. 中华普通外科学文献(电子版), 2015, 09(01): 13-17.
[2] 刘宏达, 邵祥忠, 李林, 许小伟. 海安地区动脉粥样硬化性脑梗死患者CYP2C19基因多态性及与氯吡格雷抵抗的关系[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 234-240.
[3] 任宇璐, 王舒宁, 畅锴, 杨苗. 山西地区心脑血管疾病患者CYP2C19基因多态性检测[J]. 中华临床实验室管理电子杂志, 2023, 11(03): 163-166,180.
[4] 赵瀛, 周琰, 张岚, 鞠颖慧, 张春燕, 郭玮, 潘柏申, 郭大乔. 肝细胞色素P450系统基因多态性对下肢动脉硬化闭塞症支架术后患者服用氯吡格雷的远期疗效影响[J]. 中华临床实验室管理电子杂志, 2015, 03(04): 225-229.
[5] 尹燕茹, 刘国荣, 潘晓华. 内蒙古包头地区急性缺血性脑卒中患者CYP2C19基因多态性分析[J]. 中华诊断学电子杂志, 2021, 09(01): 46-50.
[6] 吴易, 吴晓琰, 张玉. CYP2C19基因多态性对老年人联用质子泵抑制剂与氯吡格雷的抑酸和抗血小板效果的影响[J]. 中华老年病研究电子杂志, 2015, 02(03): 22-29.
[7] 杨春. 埃索美拉唑联合莫沙必利治疗贲门癌术后反流性食管炎的临床疗效观察[J]. 中华胃食管反流病电子杂志, 2015, 02(03): 135-137.
[8] 江丽华, 关灵, 黄嘉利, 韩欣良. 阿托伐他汀钙联合替格瑞洛对冠心病高血脂患者的疗效和血清细胞因子的影响[J]. 中华肥胖与代谢病电子杂志, 2021, 07(03): 165-169.
阅读次数
全文


摘要